You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
-
2024
12-25
Vebreltinib's Third Indication for NSCLC with MET Amplification was Officially Accepted by China CDE and Granted as Priority Review
On December 25, 2024, Avistone announced that its wholly-owned subsidiary, Beijing Pearl Biotechnology Co., Ltd., submitted a New Drug Application (NDA) to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for a new indication of Vebreltinib (PLB-1001). This application has been officially accepted by CDE and granted as priority review. The proposed indication is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET amplification. This milestone indicates that the field of NSCLC with MET Amplification is expected to enter a new era of precision-targeted therapy.
View Details
-
2024
11-28
Two Indications of Vebreltinib Included in the China 2024 National Reimbursement Drug List
In the newly released National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (2024), Vebreltinib, a novel MET inhibitor developed by Pearl Biotechnology, a wholly-owned subsidiary of Avistone has been successfully included.
View Details
-
2024
08-15
The KUNPENG Study of Vebreltinib's Phase II Results were Published in JCO
On July 27, 2024, the KUNPENG study, a multicenter, multi-cohort, open-label Phase II clinical study of Vebreltinib for patients with MET-abnormal advanced non-small cell lung cancer (NSCLC), led by Professor Yilong Wu’s team of Guangdong Provincial People's Hospital, was published in the internationally renowned journal Journal of Clinical Oncology (JCO, with an impact factor of IF = 42.1 in 2024). In this study, Vebreltinib has shown promising efficacy and a favorable safety profile inpatients with METex14-mutant NSCLC.
View Details
